IGI Laboratories Announces Third ANDA Submission of 2015

IGI Laboratories, Inc. recently announced it has submitted its third abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) of 2015, which brings the company’s total number of ANDA submissions now pending at the FDA to 25.

“Our team continues to execute on the targets we have established for 2015 submissions,” said Jason Grenfell-Gardner, President and CEO. “We believe the ANDA filed has an addressable market of approximately $27 million based on March 2015 data from IMS Health. We believe our current pipeline of 25 submissions, exclusive of partnered submissions, pending approval by the FDA, now has a combined addressable market of over $774 million based on March 2015 data from IMS Health.”

IGI Laboratories is a specialty generic pharmaceutical company. Its mission is to be a leading player in the specialty generic prescription drug market. For more information, visit www.igilabs.com.